# Digoxin

Drug · id `cardio:digoxin` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Lanoxin

Browse, organ or system: Heart  
Browse, condition area: Heart rhythm problems; Heart failure  

## In plain language

Digoxin, sold as Lanoxin, is a cardiac glycoside, a medicine taken by mouth in the form read here. The US label read, for Lanoxin tablets, lists three uses: mild to moderate heart failure in adults; increasing the strength of the heart muscle contraction in pediatric patients with heart failure; and controlling the ventricular response rate (how fast the lower chambers beat) in adults with chronic atrial fibrillation. For adults with heart failure the label says it improves symptoms, as shown by better exercise capacity and fewer heart-failure hospitalizations and emergency care visits, while having no effect on mortality. Its pediatric use section says safety and effectiveness for heart failure in children have not been established in adequate and well-controlled studies.

## Technical summary

RxNorm ingredient 3407; UNII 73K4184T59. RxClass lists the FDA established pharmacologic class Cardiac Glycoside; the record is filed under the class page Cardiac glycosides (digoxin) on that evidence. The label read is the Advanz Pharma (US) Corp. label for Lanoxin tablets, application NDA020405, effective 2024-12-05 in openFDA. The Lanoxin injection label (NDA009330) and generic labels were not read. The adult and pediatric statements sit in separate claims and contexts. This page records label indications, the mechanism sentence and the class only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: Children with heart failure, as described in the US label of Lanoxin tablets

Recipient: Child; Population: Pediatric patients with heart failure, as the indications and pediatric use sections of the label state. The passages read give no age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Pediatric patients, as the label states; no ages given in the passage read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of Lanoxin (digoxin tablets, Advanz Pharma (US) Corp., application NDA020405; the version dated 2024-12-05 in openFDA) says the medicine increases myocardial contractility in pediatric patients with heart failure. Its pediatric use section says the safety and effectiveness of Lanoxin in the treatment of heart failure in children have not been established in adequate and well-controlled studies.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Child; Population: Pediatric patients with heart failure, as the indications and pediatric use sections of the label state. The passages read give no age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Pediatric patients, as the label states; no ages given in the passage read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what the label says about pediatric patients with heart failure. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label passage read gives no ages. The adult indications are recorded in a separate claim. Of the label's pediatric use section, only the sentence on heart failure in children is recorded; its other statements, and the dosing and safety sections, are not. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-18
- Sources:
  1. Supports: openFDA drug label record for Lanoxin (digoxin tablets), Advanz Pharma (US) Corp. label: indications, mechanism, class (Regulator, edition The openFDA drug label record for set id d91e3646-4c63-4512-ab22-db39c085c4dc (manufacturer Advanz Pharma (US) Corp., application NDA020405), returned on 2026-11-18. The label text is dated 2024-12-05 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22d91e3646-4c63-4512-ab22-db39c085c4dc%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1.2 Heart Failure in Pediatric Patients. Retrieved 2026-11-18T17:27:12Z. Source state: Current. Version fingerprint: 9fee123e88685b3bc779cac22fdbdea9c710b43114cc0c96fe54aebd7680f0fd.
     How it applies: Label passage quoted in the research quote table (LB-07).
  2. Supports: openFDA drug label record for Lanoxin (digoxin tablets), Advanz Pharma (US) Corp. label: indications, mechanism, class (Regulator, edition The openFDA drug label record for set id d91e3646-4c63-4512-ab22-db39c085c4dc (manufacturer Advanz Pharma (US) Corp., application NDA020405), returned on 2026-11-18. The label text is dated 2024-12-05 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22d91e3646-4c63-4512-ab22-db39c085c4dc%22&limit=1>
     Locator: results\[0\].pediatric\_use\[0\], 8.4 Pediatric Use. Retrieved 2026-11-18T17:27:12Z. Source state: Current. Version fingerprint: 9fee123e88685b3bc779cac22fdbdea9c710b43114cc0c96fe54aebd7680f0fd.
     How it applies: The label's pediatric use section says safety and effectiveness for heart failure in children have not been established in adequate and well-controlled studies (LB-11).
  3. Background: openFDA drug label record for Lanoxin (digoxin tablets), Advanz Pharma (US) Corp. label: indications, mechanism, class (Regulator, edition The openFDA drug label record for set id d91e3646-4c63-4512-ab22-db39c085c4dc (manufacturer Advanz Pharma (US) Corp., application NDA020405), returned on 2026-11-18. The label text is dated 2024-12-05 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22d91e3646-4c63-4512-ab22-db39c085c4dc%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-18T17:27:12Z. Source state: Current. Version fingerprint: 9fee123e88685b3bc779cac22fdbdea9c710b43114cc0c96fe54aebd7680f0fd.
     How it applies: Effective date of the label text read, 20241205.

## Context: Adults with heart failure or chronic atrial fibrillation, as described in the US label of Lanoxin tablets

Recipient: Adult; Population: Adults with mild to moderate heart failure, and adult patients with chronic atrial fibrillation, as the indications section of the label states.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Adults, as the label states; Follow-up: Not applicable (label statement)

### The US label of Lanoxin (digoxin tablets, Advanz Pharma (US) Corp., application NDA020405; the version dated 2024-12-05 in openFDA) describes digoxin as a cardiac glycoside. It lists the treatment of mild to moderate heart failure in adults, and the control of the ventricular response rate in adult patients with chronic atrial fibrillation. For adults with heart failure the label says the medicine improves heart failure symptoms, as evidenced by improved exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Adult; Population: Adults with mild to moderate heart failure, and adult patients with chronic atrial fibrillation, as the indications section of the label states.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Adults, as the label states; Follow-up: Not applicable (label statement)
- Limitations: This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and the label's own statements about exercise capacity and hospitalization are repeated only as the label states them; no trial result is recorded for it in this atlas. The pediatric use is in a separate claim. Contraindications, warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-18
- Sources:
  1. Supports: openFDA drug label record for Lanoxin (digoxin tablets), Advanz Pharma (US) Corp. label: indications, mechanism, class (Regulator, edition The openFDA drug label record for set id d91e3646-4c63-4512-ab22-db39c085c4dc (manufacturer Advanz Pharma (US) Corp., application NDA020405), returned on 2026-11-18. The label text is dated 2024-12-05 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22d91e3646-4c63-4512-ab22-db39c085c4dc%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE. Retrieved 2026-11-18T17:27:12Z. Source state: Current. Version fingerprint: 9fee123e88685b3bc779cac22fdbdea9c710b43114cc0c96fe54aebd7680f0fd.
     How it applies: Label passage quoted in the research quote table (LB-04).
  2. Supports: openFDA drug label record for Lanoxin (digoxin tablets), Advanz Pharma (US) Corp. label: indications, mechanism, class (Regulator, edition The openFDA drug label record for set id d91e3646-4c63-4512-ab22-db39c085c4dc (manufacturer Advanz Pharma (US) Corp., application NDA020405), returned on 2026-11-18. The label text is dated 2024-12-05 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22d91e3646-4c63-4512-ab22-db39c085c4dc%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1.1 Heart Failure in Adults. Retrieved 2026-11-18T17:27:12Z. Source state: Current. Version fingerprint: 9fee123e88685b3bc779cac22fdbdea9c710b43114cc0c96fe54aebd7680f0fd.
     How it applies: Label passage quoted in the research quote table (LB-05, LB-10, LB-08).
  3. Supports: openFDA drug label record for Lanoxin (digoxin tablets), Advanz Pharma (US) Corp. label: indications, mechanism, class (Regulator, edition The openFDA drug label record for set id d91e3646-4c63-4512-ab22-db39c085c4dc (manufacturer Advanz Pharma (US) Corp., application NDA020405), returned on 2026-11-18. The label text is dated 2024-12-05 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22d91e3646-4c63-4512-ab22-db39c085c4dc%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1.3 Atrial Fibrillation in Adults. Retrieved 2026-11-18T17:27:12Z. Source state: Current. Version fingerprint: 9fee123e88685b3bc779cac22fdbdea9c710b43114cc0c96fe54aebd7680f0fd.
     How it applies: Label passage quoted in the research quote table (LB-06).
  4. Background: openFDA drug label record for Lanoxin (digoxin tablets), Advanz Pharma (US) Corp. label: indications, mechanism, class (Regulator, edition The openFDA drug label record for set id d91e3646-4c63-4512-ab22-db39c085c4dc (manufacturer Advanz Pharma (US) Corp., application NDA020405), returned on 2026-11-18. The label text is dated 2024-12-05 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22d91e3646-4c63-4512-ab22-db39c085c4dc%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-18T17:27:12Z. Source state: Current. Version fingerprint: 9fee123e88685b3bc779cac22fdbdea9c710b43114cc0c96fe54aebd7680f0fd.
     How it applies: Effective date of the label text read, 20241205.

## Connected pages

- FDA label lists mild to moderate heart failure in adults as an indication: Heart failure (`cardio:heart-failure`) [a claim, not a settled fact; see claim `cardio:claim-fda-digoxin-label-indications` and its context]
- FDA label lists control of the ventricular response rate in adults with chronic atrial fibrillation as an indication: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`) [a claim, not a settled fact; see claim `cardio:claim-fda-digoxin-label-indications` and its context]
- Files under this front: Medicines (`cardio:front-medicines`)
- The FDA established pharmacologic class of digoxin in RxClass is Cardiac Glycoside: Cardiac glycosides (digoxin) (`cardio:cardiac-glycosides-digoxin`)

## Provenance

Content hash: 2c77036e6fc89c1fee24f6afd40546c689ef7aad1873464f7ee79de11fe47834
Last substantive edit: 2026-11-18
Evidence last checked: 2026-11-18
